Sugi Predict

Sugi Predict / Compounds / SCHEMBL1455249

SCHEMBL1455249

SCHEMBL1455249

CC(C)(O[C]=O)c1ccc(/N=N/c2ccccc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.41
▸ MAPT P10636 6/20 0.41
▸ RAB9A P51151 3/20 0.41
▸ CASP3 P42574 1/20 0.41
▸ SENP8 Q96LD8 1/20 0.41
▸ SENP7 Q9BQF6 1/20 0.41
▸ SENP6 Q9GZR1 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ MAPK1 P28482 4/20 0.39
▸ PPARA Q07869 4/20 0.39
▸ TDP1 Q9NUW8 3/20 0.39
▸ TSHR P16473 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ TRPA1 O75762 1/20 0.39
▸ MEN1 O00255 4/20 0.38
▸ KMT2A Q03164 4/20 0.38
▸ NPC1 O15118 2/20 0.38
▸ PKM P14618 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1455251 1.00 ALDH1A1 (0.41) ALDH1A1MAPTRAB9ACASP3SENP8
SCHEMBL135667 0.83 MAPK1 (0.56) ALDH1A1MAPTMAPK1TSHRMEN1
SCHEMBL9461 0.80 MAPK1 (0.43) ALDH1A1MAPTCASP3SENP8SENP7
SCHEMBL14661199 0.78 PPARA (0.36) ALDH1A1MAPTRAB9ACASP3SENP8
SCHEMBL904520 0.78 MAPT (0.38) ALDH1A1MAPTRAB9ACASP3SENP8
SCHEMBL1207238 0.76 PTGS2 (0.41) ALDH1A1RAB9ACASP3SENP8SENP7
SCHEMBL1455254 0.76 ALDH1A1 (0.41) ALDH1A1MAPTRAB9ACASP3SENP8
SCHEMBL138150 0.74 TSHR (0.46) ALDH1A1MAPTRAB9AMAPK1TDP1
SCHEMBL3293150 0.73 MAPT (0.46) ALDH1A1MAPTRAB9ACASP3SENP8
SCHEMBL113257 0.73 MAPT (0.46) ALDH1A1MAPTRAB9ACASP3SENP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240240181-A1 NEUROPROTECTIVE MOLECULES AND METHODS OF TREATING NEUROLOGICAL DISORDERS AND INDUCING STRESS GRANULES THE BRIGHAM AND WOMEN'S HOSPITAL, INC. 2024-07-18 — — US disclosed
US-20230414790-A1 miRNA PROFILING COMPOSITIONS AND METHODS OF USE THE GENERAL HOSPITAL CORPORATION (US) 2023-12-28 — — US disclosed
US-20210332359-A1 COMPOSITIONS AND METHODS FOR IMMUNE CHECKPOINT INHIBITION THE GENERAL HOSPITAL CORPORATION 2021-10-28 — — US disclosed
US-20210106679-A1 Silaffin Silica Particle Adjuvant Universität Wien (AT) 2021-04-15 — — US disclosed
EP-3612216-A1 SILAFFIN SILICA PARTICLE ADJUVANT Universität Wien (AT) 2020-02-26 — — EP disclosed
CN-110785182-A Silavidin (SILAFFIN) silica particle adjuvants 维也纳大学 2020-02-11 — — CN disclosed
US-10463627-B2 Therapeutic nanoparticles and methods of use thereof THE GENERAL HOSPITAL CORPORATION (US) 2019-11-05 — — US disclosed
US-10457939-B2 Neuroprotective molecules and methods of treating neurological disorders and inducing stress granules THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2019-10-29 — — US disclosed
WO-2018193039-A1 SILAFFIN SILICA PARTICLE ADJUVANT Universität Wien (AT) 2018-10-25 — — WO disclosed
US-10086093-B2 miRNA profiling compositions and methods of use THE GENERAL HOSPITAL CORPORATION (US) 2018-10-02 — — US disclosed
US-20110306615-A1 NOVEL IMIDAZOLIDINE DERIVATIVE AND USE THEREOF CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-12-15 — — US disclosed
US-8022047-B2 Combination anticancer agents CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-09-20 — — US disclosed
US-7910593-B2 Water-soluble prodrugs CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-03-22 — — US disclosed
US-20090149478-A1 NOVEL COMBINATION ANTICANCER AGENTS CHUGAI SEIYAKU KABUSHIKI KAISHA 2009-06-11 — — US disclosed
US-20090118271-A1 Preventive or Therapeutic Agents for Pancreatic Cancer, Ovarian Cancer, or Liver Cancer Comprising a Novel Water-Soluble Prodrug CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2009-05-07 — — US disclosed
EP-1938823-A1 AGENT FOR PREVENTING OR TREATING PANCREAS CANCER, OVARY CANCER OR LIVER CANCER CONTAINING NOVEL WATER-SOLUBLE PRODRUG CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2008-07-02 — — EP disclosed
EP-1925309-A1 NOVEL ANTICANCER CONCOMITANT DRUG CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2008-05-28 — — EP disclosed
US-20080015157-A1 Novel Water-Soluble Prodrugs CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2008-01-17 — — US disclosed
EP-1790640-A1 NOVEL IMIDAZOLIDINE DERIVATIVE AND USE THEREOF CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2007-05-30 — — EP disclosed
EP-1757609-A1 NOVEL WATER-SOLUBLE PRODRUG CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2007-02-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110306615-A1 NOVEL IMIDAZOLIDINE DERIVATIVE AND USE THEREOF CBR1, NR0B1, CNKSR1 ALDH1A1 989/4885MAPT 4811/4885RAB9A 1308/4885
US-20090149478-A1 NOVEL COMBINATION ANTICANCER AGENTS KRAS, TOP1, ERBB3 ALDH1A1 495/4885MAPT 4153/4885RAB9A 257/4885
US-20210106679-A1 Silaffin Silica Particle Adjuvant MICA, SF3A1, SFXN1 ALDH1A1 4861/4885MAPT 4245/4885RAB9A 2335/4885
US-20080015157-A1 Novel Water-Soluble Prodrugs ADH1A, ADH1C, SLC43A1 ALDH1A1 142/4885MAPT 3789/4885RAB9A 1405/4885
US-20090118271-A1 Preventive or Therapeutic Agents for Pancreatic Cancer, Ovarian Cancer, or Liver Cancer Comprising a Novel Water-Soluble Prodrug TP53, SLC10A1, BRCA1 ALDH1A1 429/4885MAPT 4575/4885RAB9A 1786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.